margetuximab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
chimeric origin	5434	1350624-75-7

Description:

Molecule	Description
Molfile Synonyms: margetuximab margetuximab-cmkb margenza MGAH22	Margetuximab-cmkb, a HER2/neu receptor antagonist, is a chimeric Fc-engineered IgG1 kappa monoclonal antibody. It binds to the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2). Upon binding to HER2-expressing tumor cells, margetuximab-cmkb inhibits tumor cell proliferation, reduces shedding of the HER2 extracellular domain and mediates antibody-dependent cellular cytotoxicity (ADCC). Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Molfile

Synonyms:

margetuximab
margetuximab-cmkb
margenza
MGAH22

Margetuximab-cmkb, a HER2/neu receptor antagonist, is a chimeric Fc-engineered IgG1 kappa monoclonal antibody. It binds to the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2). Upon binding to HER2-expressing tumor cells, margetuximab-cmkb inhibits tumor cell proliferation, reduces shedding of the HER2 extracellular domain and mediates antibody-dependent cellular cytotoxicity (ADCC).

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Dec. 16, 2020	FDA	MACROGENICS INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01FD06	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
MeSH PA	D000970	Antineoplastic Agents
FDA MoA	N0000020008	HER2/Neu/cerbB2 Antagonists
FDA EPC	N0000175661	HER2/neu Receptor Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Metastatic human epidermal growth factor 2 positive carcinoma of breast	indication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN	ANTAGONIST	Kd	8.55		DRUG LABEL	DRUG LABEL
Low affinity immunoglobulin gamma Fc region receptor III-A	Membrane receptor	P08637	FCG3A_HUMAN	ANTAGONIST	Kd	7.05		DRUG LABEL	DRUG LABEL

External reference:

ID	Source
D10446	KEGG_DRUG
K911R84KEW	UNII
C4053695	UMLSCUI
CHEMBL2364649	ChEMBL_ID
DB14967	DRUGBANK_ID
8686	IUPHAR_LIGAND_ID
018597	NDDF
1144474002	SNOMEDCT_US
1144506004	SNOMEDCT_US
4040181	VANDF
4040182	VANDF
2473850	RXNORM
341786	MMSL
39092	MMSL
d09695	MMSL
C000617981	MESH_SUPPLEMENTAL_RECORD_UI
9799	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
MARGENZA	HUMAN PRESCRIPTION DRUG LABEL	1	74527-022	INJECTION, SOLUTION, CONCENTRATE	25 mg	INTRAVENOUS	BLA	29 sections
MARGENZA	HUMAN PRESCRIPTION DRUG LABEL	1	74527-022	INJECTION, SOLUTION, CONCENTRATE	25 mg	INTRAVENOUS	BLA	29 sections